Galeria Teams Up With Blue Yonder to Enhance the In-Store and Online Customer Shopping Experience
13.5.2025 10:00:00 CEST | Business Wire | Press Release
In today's rapidly evolving retail landscape, consumers increasingly seek personalized shopping experiences tailored to meet their specific demand requirements. For omni-channel retailers, success depends on seamlessly delivering high-quality products and excellent customer service powered by advanced technology that effectively supports a demand-driven, omni-channel strategy.
That is why Galeria, Germany´s leading department store chain, has chosen to deploy Blue Yonder’s demand and replenishment capabilities to strengthen its supply chain and enhance operational efficiency. This strategic investment enables the retailer to deliver a highly responsive and seamless shopping experience across both in-store and online channels, reinforcing Galeria's commitment to quality and convenience.
Galeria previously relied mainly on manual processes that limited the company’s ability to forecast demand and accurately allocate inventory across its stores. Through strong collaboration between Galeria's IT, purchasing and supply chain teams and Blue Yonder, the teams were able to significantly improve the retailer’s data quality, availability, and business process efficiency. The collaboration was also pivotal in establishing well-defined system interfaces to support seamless data integration and automation. A crucial milestone in this transformation was the development of a robust forecasting model, built through extensive analysis of transactional and promotional data.
"Galeria's supply chain management is undergoing a significant transformation, with a primary focus on boosting customer satisfaction,” said Moritz Winter, chief supply chain officer, Galeria. “To achieve this, it was crucial to enhance both stock availability and allocation accuracy. There was an urgent need to improve the management of allocations and replenishments, streamline business processes, and implement standardization and automation. Galeria recognized Blue Yonder as the ideal supply chain solutions provider for this transformation.”
"Blue Yonder’s demand and replenishment capabilities provide a high level of standardization, AI-driven forecasting, and process simplification, making them a perfect fit for our needs,” said Alexander Rings, director, inventory management & buying analytics, Galeria. “The implementation was initially designed to help us transform into a customer- and demand-driven supply chain by leveraging software as an enabler; however, it also reshaped our understanding of central business processes and needs. While stock availability increased significantly, we are in parallel working on fundamentally improving data and buying processes."
With Blue Yonder’s AI-powered demand and replenishment capabilities, Galeria will be able to:
- Utilize a fully automated machine learning model that enhances supply chain agility and resilience, allowing rapid adaptation to local demand, market shifts, and external factors.
- Improve customer service levels by aligning inventory with actual demand, reducing the risk of stockouts, minimizing overstocking, and reducing waste.
- Streamline lifecycle management, especially for seasonal and promotional products.
- Accelerate new product introductions and optimize seasonal assortment plans.
- Enhance end-of-life product management, reducingmarkdowns and excess inventory through demand pattern analysis.
With Blue Yonder’s capabilities now live, Galeria can forecast, plan, and execute with greater accuracy – optimizing inventory, improving fulfillment, and driving operational efficiency across both in-store and online channels. This transformation not only strengthens Galeria’s supply chain but also deepens customer loyalty through a seamless shopping experience.
“We are proud to collaborate with Galeria to optimize their supply chain. As Galeria continues its business and processes innovation, we look forward to being a key solution provider and advisor in their journey, ensuring that their supply chain evolves alongside their success," said Vince Beacom, president, global retail, Blue Yonder.
Additional Resources:
- Learn more about Blue Yonder solutions for Retail Planning
- Learn more about Blue Yonder solutions for Apparel and Footwear
About Galeria
With around 185 million visitors a year and 83 stores in around 70 cities, GALERIA S.à r.l. & Co. KG, the largest department store in Germany, always has one goal in mind: to focus on its customers. Versatility, regionality and strategic partnerships play a decisive role in this. A mix of modern brands, paired with quality and first-class service, characterize the innovative and inspiring shopping experience. GALERIA analyzes its target groups precisely and is therefore the market leader in categories such as lingerie, luggage and accessories. The market halls and restaurants round off the shopping offer in the department stores. In addition to the stationary range, GALERIA offers around 1,500 brands on its online marketplace, www.galeria.de. All this makes GALERIA one of the most important shopping destinations in the heart of German city centers. More information at www.galeria.de.
About Blue Yonder
Blue Yonder is the world leader in end-to-end digital supply chain transformation. With a unified, AI-driven platform and multi-tier network, Blue Yonder empowers businesses to operate sustainably, scale profitably, and delight their customers — all at machine speed. Blue Yonder’s modern supply chain innovations and unmatched industry expertise help more than 3,000 retailers, manufacturers, and logistics service providers to confidently navigate supply chain complexity and disruption. blueyonder.com
“Blue Yonder” is a trademark or registered trademark of Blue Yonder Group, Inc. Any trade, product or service name referenced in this document using the name “Blue Yonder” is a trademark and/or property of Blue Yonder Group, Inc. All other company and product names may be trademarks, registered trademarks or service marks of the companies with which they are associated.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250513357648/en/
Contacts
Blue Yonder Corporate Communications:
mediarelationsteam@blueyonder.com
U.S.: +1 480-308-3037
EMEA: +39 335 7849149
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom